Beam Therapeutics reports improved patient-reported outcomes in risto-cel sickle cell trial
BEAM•Beam Therapeutics said initial patient-reported outcomes in its Phase 1/2 BEACON trial showed early, sustained improvements in physical function, pain and overall well-being compared with baseline. It will present updated results on December 12, 2026, and expects a U.S. biologics license application as early as year-end 2026.
1. Trial results
Beam Therapeutics will present updated Phase 1/2 BEACON trial results for its sickle cell therapy risto-cel at ASH on December 12, 2026. Initial patient-reported outcomes showed early, sustained improvements in physical function, pain and overall well-being compared with baseline.
2. Filing timeline
The company expects to submit a U.S. biologics license application for the investigational cell therapy as early as year-end 2026.
